Dallas, Texas, United States, and Dublin, Ireland, November 19, 2026
Nanoscope Therapeutics, Inc. has entered into an exclusive partnership with Uniphar to expand patient access to MOGENRY® (sonpiretigene isteparvovec; MCO-010) across the six member states of the Gulf Cooperation Council (GCC). Under the agreement, Uniphar will serve as Nanoscope’s exclusive named patient sales and commercialisation partner for the investigational optogenetic gene therapy in Saudi Arabia, the United Arab Emirates, Kuwait, Qatar, Bahrain and Oman. The collaboration is intended to establish pathways for eligible patients with inherited retinal dystrophies (IRDs), including retinitis pigmentosa, to access the treatment through named patient supply programmes before local marketing authorisations are granted. Uniphar will also provide regional commercialisation services as the required regulatory approvals are secured. The agreement represents an important step in Nanoscope’s international commercial readiness strategy and aims to support patients affected by inherited retinal conditions for which treatment options remain limited. The partnership combines Nanoscope’s gene therapy development capabilities with Uniphar’s regional healthcare infrastructure, regulatory expertise and pharmaceutical distribution services. Importantly, MOGENRY remains investigational and is not approved for commercial sale in any GCC country.
Uniphar to Support Patient Access Across Six GCC Markets
Under the agreement, Uniphar will coordinate named patient access and support the future commercialisation of MOGENRY across the six GCC countries. Its responsibilities will include local regulatory and registration support, pricing and market access planning, medical affairs, medical information, pharmacovigilance support, temperature-controlled importation and distribution, and patient support services. These activities are intended to establish the infrastructure needed to support access in accordance with the regulatory requirements of each country. The named patient supply pathway may allow eligible patients to receive treatment ahead of local marketing authorisation, subject to a treating physician’s request and applicable national laws. Nanoscope will retain ownership of all marketing authorisations for MOGENRY in the region. The agreement also supports demand forecasting, inventory management, physician education and compliance with regional quality and safety requirements. Uniphar’s experience in pharmaceutical and biotechnology services is expected to support the operational requirements of introducing an investigational rare-disease therapy into multiple healthcare systems. The collaboration is designed to establish a foundation for broader commercialisation if the necessary country-specific regulatory approvals are obtained.
MOGENRY Uses an Optogenetic Approach to Address Retinal Degeneration
MOGENRY (sonpiretigene isteparvovec; MCO-010) is an investigational, one-time, in-office intravitreal optogenetic gene therapy developed using Nanoscope’s proprietary Multi-Characteristic Opsin (MCO) platform. It is designed for patients experiencing photoreceptor loss and vision impairment associated with retinal degenerative diseases. Unlike gene therapies that target a specific inherited genetic mutation, MOGENRY is designed to work independently of the underlying genetic cause of the retinal condition. The therapy delivers a genetically engineered synthetic opsin gene to surviving retinal bipolar cells, making these cells directly sensitive to light. This approach aims to use the remaining visual circuitry after photoreceptor loss and potentially restore visual function. The company says the treatment does not require genetic testing, invasive surgery or repeat dosing and is administered as a one-time injection within an ophthalmology practice. MOGENRY has received an Orphan Drug designation for inherited retinal dystrophies from the Saudi Food and Drug Authority (SFDA). This designation is a regulatory development milestone and should not be confused with marketing approval.
Regulatory Progress and Global Development Programme
Nanoscope is advancing MOGENRY through regulatory and clinical development programmes in several markets. In the United States, the FDA has accepted and filed the company’s Biologics License Application (BLA) for the treatment of retinitis pigmentosa (RP) with severe vision loss. The application is supported by results from the RESTORE Phase 2b/3 clinical trial, which evaluated the investigational therapy in patients with RP. In Japan, the Pharmaceuticals and Medical Devices Agency (PMDA) has accepted the company’s New Drug Application for MOGENRY for inherited retinal dystrophies and granted priority review. The company has also reported results from the STARLIGHT Phase 2 clinical trial evaluating MCO-010 in Stargardt disease and plans to initiate a Phase 3 registrational study for that condition. The Uniphar agreement complements Nanoscope’s broader commercial preparation activities, including its previously announced selection of InspiroGene by McKesson to provide U.S. commercialisation services, subject to regulatory approval. Together, these initiatives reflect the company’s efforts to prepare for potential market access while continuing regulatory engagement and clinical development. The GCC partnership is therefore an important expansion of Nanoscope’s global strategy, although access and commercialisation remain dependent on applicable regulatory requirements.
Source: Nanoscope Therapeutics, Uniphar press release


